Overview

Location [1]
11q13.3
Pathway
Receptor tyrosine kinase/growth factor signaling
Protein [2]
Fibroblast growth factor 19
Synonyms [1]
-

Fibroblast growth factor 19 (FGF19) is a gene that encodes a protein with mitogenic activity that functions as a FGF4 heparin dependent ligand. Missense and silent mutations are observed in cancers such as esophageal cancer, intestinal cancer, and skin cancer.

FGF19 is altered in 4.88% of all cancers with breast carcinoma, non-small cell lung carcinoma, melanoma, bladder carcinoma, and head and neck squamous cell carcinoma having the greatest prevalence of alterations [3].

FGF19 GENIE Cases - Top Diseases

The most common alterations in FGF19 are FGF19 Amplification (2.69%), FGF19 Mutation (0.25%), FGF19 Loss (0.02%), FGF19 R127C (0.01%), and FGF19 D198N (0.00%) [3].

FGF19 GENIE Cases - Top Alterations

Significance of FGF19 in Diseases

Malignant Solid Tumor +

Urothelial Carcinoma +

Hepatocellular Carcinoma +

Multiple Myeloma +

Esophageal Carcinoma +

Nasopharyngeal Carcinoma +

Squamous Cell Lung Carcinoma +

Gastric Carcinoma +

Anaplastic Oligodendroglioma +

Cholangiocarcinoma +

Intrahepatic Cholangiocarcinoma +

Endometrial Carcinoma +

Glioblastoma +

Anaplastic Astrocytoma +

Cancer +

Extrahepatic Cholangiocarcinoma +

Myeloproliferative Neoplasm +

Ovarian Carcinoma +

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20170629. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.